Similarly, the study has found that LVI is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy, some scholars also have found that the occurrence of LVI is significantly related to luminal B with HER2(-), and the basal-like subtype [20]. This evidence concerns the gene ERBB2 and breast cancer.